Janus Henderson Group
BBIO icon

Janus Henderson Group’s BridgeBio Pharma BBIO Stock Holding History

Janus Henderson Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$979M Buy
13,179,013
+2,178,556
+20% +$158M 0.47% 39
2025
Q4 		$841M Buy
11,000,457
+2,259,378
+26% +$148M 0.38% 55
2025
Q3 		$454M Sell
8,741,079
-535,453
-6% -$26.1M 0.21% 109
2025
Q2 		$401M Buy
9,276,532
+2,105,133
+29% +$76.6M 0.2% 116
2025
Q1 		$252M Buy
7,171,399
+2,263,866
+46% +$76.3M 0.14% 164
2024
Q4 		$135M Buy
4,907,533
+89,521
+2% +$2.31M 0.07% 242
2024
Q3 		$123M Buy
4,818,012
+505,481
+12% +$13.3M 0.06% 250
2024
Q2 		$109M Buy
4,312,531
+999,825
+30% +$27.3M 0.06% 252
2024
Q1 		$102M Buy
3,312,706
+2,169,143
+190% +$73.8M 0.06% 262
2023
Q4 		$46.2M Sell
1,143,563
-50
-0% -$1.5K 0.03% 390
2023
Q3 		$30.2M Buy
1,143,613
+1,100,120
+2,529% +$31.2M 0.02% 457
2023
Q2 		$748K Sell
43,493
-60,975
-58% -$917K ﹤0.01% 1751
2023
Q1 		$1.73M Buy
104,468
+90,640
+655% +$1.06M ﹤0.01% 1342
2022
Q4 		$105K Sell
13,828
-13,830
-50% -$132K ﹤0.01% 2325
2022
Q3 		$274K Buy
27,658
+13,592
+97% +$141K ﹤0.01% 2254
2022
Q2 		$128K Buy
14,066
+218
+2% +$1.82K ﹤0.01% 2431
2022
Q1 		$141K Sell
13,848
-14
-0.1% -$144 ﹤0.01% 2510
2021
Q4 		$231K Sell
13,862
-2,631,579
-99% -$111M ﹤0.01% 2326
2021
Q3 		$124M Sell
2,645,441
-165,211
-6% -$8.86M 0.05% 324
2021
Q2 		$171M Sell
2,810,652
-62,531
-2% -$3.57M 0.07% 270
2021
Q1 		$177M Buy
2,873,183
+1,089,648
+61% +$71.3M 0.08% 242
2020
Q4 		$127M Buy
1,783,535
+92,074
+5% +$4.44M 0.06% 312
2020
Q3 		$63.5M Sell
1,691,461
-74,403
-4% -$2.34M 0.03% 439
2020
Q2 		$57.6M Sell
1,765,864
-20,175
-1% -$615K 0.03% 454
2020
Q1 		$51.8M Sell
1,786,039
-1,355,042
-43% -$42M 0.04% 448
2019
Q4 		$110M Buy
3,141,081
+2,688,910
+595% +$74.5M 0.06% 340
2019
Q3 		$9.71M Buy
452,171
+106,182
+31% +$2.94M 0.01% 954
2019
Q2 		$9.33M Buy
+345,989
New +$9.43M 0.01% 960

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group's BBIO Position: Q1 2026 in Review

Janus Henderson Group increased its BridgeBio Pharma (BBIO) stake by 20% in Q1 2026, buying an estimated $158M and bringing the position to 13,179,013 shares worth $979M. The position accounts for 0.47% of the portfolio, ranked #39.

Janus Henderson Group first reported a position in BBIO in Q2 2019 and has held it in 28 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Janus Henderson Group held 13,179,013 shares of BridgeBio Pharma worth $979M as of Q1 2026.
  • Janus Henderson Group bought 2,178,556 BridgeBio Pharma shares in Q1 2026, an estimated $158M.
  • BridgeBio Pharma made up 0.47% of Janus Henderson Group's portfolio in Q1 2026, its #39 holding.
  • Janus Henderson Group first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 28 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.